further investigation is needed to clarify whether this relationship is mediated via iron metabolism.
Introduction
Diabetes mellitus is a recognised complication of excessive iron accumulation due to increased absorption and retention of dietary iron in the setting of hereditary haemochromatosis, and transfusion-dependent iron overload [1, 2] . Proposed underlying mechanisms include roles for iron accumulation in both beta cell failure and insulin resistance, with insulin resistance being more relevant to diabetes risk in the setting of transfusion or diet-related iron excess [2] . Serum ferritin levels are commonly utilised as a marker of body iron stores, and both dietary iron intake and higher ferritin levels predict incidence of Type 2 diabetes in epidiemological studies [3] [4] [5] . Conversely, iron restriction improves glycemia in diabetic rats [6] and phlebotomy reduces HbA1c levels in patients with Type 2 diabetes who have high ferritin levels [7] . However it remains unclear whether higher ferritin levels are a manifestation of excessive body iron stores which interfere directly with glucose metabolism; or represent a marker of systemic processes such as inflammation which correlate to diabetes risk [2] .
In prospective studies, dietary iron intake in the form of heme from meat products and serum ferritin levels predict incidence of Type 2 diabetes but these associations are attenuated by adjustment for markers of inflammation [8] . Furthermore, there is doubt over whether a doseresponse effect exists with a non-linear association being reported in a recent meta-analysis [9] . Recently, iron has been found to negatively regulate adiponectin, an insulin-sensitising adipokine, suggesting that adiponectin may mediate the relationship between iron and glucose metabolism [10] . To clarify whether or not ferritin and other markers of iron metabolism are associated independently with diabetes risk, we analysed the association of serum ferritin, iron and transferrin with diabetes risk with adjustment for conventional risk factors, the inflammatory marker C-reactive protein (CRP) and adiponectin in a large cohort of community-dwelling adult men and women.
Participants and Methods

Study population
Busselton is a coastal town in Western Australia, whose residents have participated in a series of health surveys from 1966 onwards. In 1994-1995, all surviving subjects of earlier Busselton surveys were invited to participate in a follow-up survey [11] . More than 90% of the Busselton population is of Caucasian ethnic origin. The present study is based on 4,185 men and women aged 19-97 years who attended the 1994/95 survey and provided blood samples for analysis. The study was approved by the Human Research Ethics Committee of the University of Western Australia, and all participants provided written informed consent.
Assessment of medical comorbidities
Methods used in the Busselton Health Survey have been described previously [11] .
Participants were asked to complete a comprehensive health and lifestyle questionnaire and underwent a physical assessment. Blood pressure was measured using a mercury sphygmomanometer after five minutes at rest in a sitting position. Height was measured using a stadiometer and weight in light underclothes. Smoking, diabetes, and the use of antihypertensive or glucose-lowering medications were obtained via questionnaire.
Participants were defined as having diabetes if they reported being told by a doctor that they had diabetes, and/or had a fasting blood glucose ≥7.0 mmol/L, or were taking glucoselowering medications. Participants were considered to have Type 2 diabetes unless they (i) reported age of onset <40 years and were commenced on insulin at diagnosis, or (ii) had age of onset between 40-60 years, were commenced on insulin from the time of diagnosis, were on insulin at recruitment and had body mass index (BMI) <30 kg/m 2 [12] . Other medical history was assessed from questionnaire responses and also via the Western Australian Data
Linkage System (WADLS), which captures electronically all admissions to public or private hospitals in Western Australia [13] . A history of coronary heart disease (CHD) or stroke was defined as any hospital admission with a primary or secondary diagnosis of CHD or stroke during the preceding 15 years prior to the survey.
Laboratory assays
Blood samples were collected in the early morning after an overnight fast. Serum ferritin, iron and transferrin saturation, and mutations in the HFE gene were assessed as previously reported [14] . Briefly, serum ferritin levels were measured by chemiluminescence immunoassay (ACS-180, Chiron Diagnostics, Norwood, Massachusetts, USA). Serum iron levels were measured by a standard colorimetric method and serum transferrin levels by immunoturbidimetry on an automated analyser (Model 917, Hitachi, Toyko, Japan). Serum transferrin saturation values were calculated as follows: ([serum iron/2]*serum transferrin)*100. DNA was extracted from whole blood and PCR analysis performed to identify C282Y and H63D mutations of the HFE gene. Other biochemical analyses were performed as previously described [15] . Briefly, fasting serum cholesterol, HDL and triglycerides were determined at the time of the survey by standard enzymatic methods (Hitachi 747 analyser, Roche Diagnostics, Australia). Glucose was measured using a hexokinase assay. Insulin was assayed using a Tosoh A1A-600 immunoassay analyzer using a two-site immunoenzymometric assay. We measured C-reactive protein (CRP) using a particle-enhanced immunoturbidimetric assay on a Modular analyser (Roche Diagnostics, Germany). Plasma adiponectin levels were measured by a commercially available quantitative sandwich enzyme immunoassay technique (R&D Systems Inc., Minneapolis, Minnesota, USA). We estimated insulin resistance using homeostatic models (HOMA-R) as previously described [16] . Adults with glucose ≤3.5 or >25 mmol/L were excluded.
HOMA-R was calculated as (insulin*glucose)/22.5 and was log transformed for analyses.
Statistical analyses
Descriptive statistics are presented as mean and standard deviation (SD) or as percentages (Table 1) . Logistic regression models were used to examine the relationships between serum ferritin, iron and transferrin saturation as continuous variables and categorised into tertiles with the presence of diabetes in men and women (Tables 2-4 ). Models were adjusted sequentially for variables that could potentially modify their association with prevalent diabetes. Models were age-adjusted, then additionally adjusted for smoking, alcohol consumption, CHD or stroke history, BMI, waist, systolic and diastolic blood pressure, highdensity lipoprotein cholesterol (HDL), triglycerides, CRP, adiponectin, alanine transaminase (ALT) and gamma-glutamyl transpeptidase (GGT). Variables were log transformed where the original distributions were skewed. To identify the important and independent correlates of (log) HOMA-R in non-diabetic men and women we fitted a multivariable model (Table 5) .
A p value of <0.05 or 95% confidence intervals that did not cross 1.0 were regarded as significant.
Results
Characteristics of the study population
The age ranges for men and women were 16.9 to 97.3 and 16.5 to 92.2 years respectively. for analysis. Characteristics of the study cohort stratified by gender and the presence or absence of diabetes are shown (Table 1 ). Serum ferritin, iron and transferrin saturation are shown without and with log transformation and as tertiles. Men with diabetes were older, more likely to have smoked and less likely to be current drinkers. In men, diabetes was associated with a history of cardiovascular disease, higher BMI and waist circumference, systolic and diastolic blood pressure, triglycerides, fasting glucose, insulin, HOMA-R, GGT
and CRP, but with lower HDL. These cardiometabolic variables were similarly associated with diabetes in women with the exceptions of smoking and diastolic blood pressure, as was menopausal status. Ferritin levels were significantly higher in men and women with diabetes, when examined as both continuous variables and in tertiles. Serum iron was not associated with diabetes in either men or women. Lower transferrin saturation was associated with diabetes when analysed as a log transformed variable or in tertiles in men but not in women.
TABLE 1
Association of ferritin with prevalent diabetes
In men, ferritin was significantly associated with diabetes when examined as a continuous variable and in tertile groups after adjustment for age alone ( Table 2 ). The association of ferritin as a continuous variable with diabetes remained significant in further models that adjusted for all other cardiometabolic risk factors including CRP, adiponectin, ALT and GGT with an odds ratio (OR) of 1.29 per 1 unit increase log ferritin (95% confidence interval
[CI]=1.01-1.65). In women, there was also a significant association between ferritin and diabetes ( 
Regression analysis of transferrin saturation and prevalent diabetes
Of the 1,834 men and 2,351 women analysed, there were 57 men (6 diabetic and 51 nondiabetic) and 29 women (1 diabetic and 28 non-diabetic) with transferrin saturation >50%. In men, there was some evidence of a negative association between transferrin saturation and diabetes after adjustment for age alone. 
Multivariable analysis of factors associated with insulin resistance
The fitted multivariable model examining factors associated with insulin resistance as estimated using HOMA-R is shown for men and women without diabetes (Table 5 ). In men, age was negatively associated with HOMA-R, as were HDL. CHD or stroke history, BMI, waist circumference, systolic blood pressure, triglycerides, CRP and ALT were positively associated with HOMA-R in men. In women, age, use of hormone replacement therapy in post-menopausal women, and HDL were negatively associated with HOMA-R.
BMI, waist circumference, systolic blood pressure, triglycerides and GGT were positively associated. Adiponectin was inversely associated with HOMA-R in both men and women.
Ferritin was not associated with HOMA-R in either men or women without diabetes.
TABLE 5
Discussion
Higher serum ferritin levels are independently associated with diabetes in men and women, both in age-adjusted and in multivariable adjusted models accounting for cardiometabolic factors. This association is present for ferritin analysed as a continuous variable, and in women for ferritin levels in the highest tertile of values. However neither serum iron nor transferrin saturation were associated with diabetes in this cohort. Furthermore, ferritin was not associated with insulin resistance in men or women without diabetes.
Our results are consistent with previous studies relating serum ferritin levels to diabetes risk [3] [4] [5] [17] [18] [19] . However, higher ferritin levels are also associated with obesity and the metabolic syndrome [20, 21] and with cardiovascular risk [22] . There is also a recognised association between ferritin levels and the presence and severity of fatty liver disease [23] .
We found that the association of serum ferritin with prevalent diabetes was largely unchanged after adjustment for cardiometabolic risk factors including adiponectin, and it remained significant after adjustment for ALT and GGT. Therefore, our results suggest that the relationship between ferritin level and diabetes risk is not modulated by the presence of obesity or by common risk factors for cardiovascular disease and diabetes. Furthermore, in our analysis ferritin was not independently associated with insulin resistance as assessed using HOMA-R in men or women without diabetes. This contrasts with previous reports implicating ferritin levels with insulin resistance syndromes and with hyperinsulinaemia [20, 21, 24, 25] . Therefore, while the association between higher ferritin and diabetes is robust, the mechanisms by which ferritin might contribute to diabetes risk remains unclear.
We measured serum iron and transferrin saturation to provide additional indicators of body iron stores [26] . Transferrin serves as the major vehicle for iron delivery into cells via the transferrin receptor, with increased saturation reflective of higher body iron stores [26] .
Previous studies have indicated that transferrin saturation ≥50% is associated with increased risk of diabetes [27, 28] . However, we found no association of either serum iron or transferrin saturation with diabetes in men or women, with the large majority of our study participants having transferrin saturation below this threshold. By contrast, there was a trend for higher transferrin saturation to be associated with lower risk of diabetes in men, although this was not significant in the fully adjusted models. Nevertheless, the trend is in the opposite direction from that expected should higher body iron stores contribute to diabetes risk. We found no evidence to support the concept that iron availability as reflected by serum iron or transferrin saturation contributes to diabetes risk. Previous epidemiological studies have shown associations of not only ferritin levels [3] [4] [5] but also dietary heme iron intake with risk of Type 2 diabetes [3, 8, 9] . We did not have data on dietary intake in our cohort however our examination of iron status included serum iron and transferrin saturation in addition to ferritin. The discordance between associations of ferritin with Type 2 diabetes and the absence of any association of serum iron or transferrin saturation are consistent with ferritin being a marker of metabolic risk distinct from iron metabolism.
In addition to being an indicator of body iron stores, circulating ferritin is an acute phase reactant which like CRP is elevated in inflammatory conditions, while transferrin is not [29] .
Inflammation is a mediator of diabetes risk and higher levels of CRP are associated with impaired glucose tolerance and diabetes [30, 31] . Adiponectin is has also been proposed as a mediator of inflammatory responses and insulin sensitivity [32] . However, adjustment for CRP and for adiponectin in the final multivariate model did not alter the association of ferritin with diabetes in men and women. Therefore, measurement of ferritin captures a key determinant of diabetes risk that is not achieved via measurement of either CRP, adiponectin or both. Ferritin is a robust biomarker for diabetes in our study population, but the negative associations of iron and transferrin saturation with diabetes lead us to postulate that mechanisms independent of body iron status are involved.
Strengths of our study are the large size of the cohort, its inclusion of men and women spanning younger, middle and older ages, extensive phenotyping and availability of physical, metabolic and laboratory variables for the analyses. As this cohort had previously been studied to evaluate the clinical expression of hereditary haemochromatosis [14] , genotyping data were available and we were able to exclude men and women with C282Y and H63D polymorphisms associated with this disease. We compared associations not only of ferritin but also serum iron and transferrin saturation, we conducted analyses adjusting for a wide range of potential confounders and explored the influence of CRP and adiponectin. We acknowledge several limitations of this study. This is an observational study and we performed a cross-sectional analysis thus we cannot infer causation. The men and women were community-dwelling survivors from previous surveys, thus a "healthy survivor" effect might be present. We did not have serial blood samples to assess longitudinal changes in the levels of ferritin, iron and transferrin instead we used a single blood sample albeit collected early in the morning in the fasted state. While HOMA-R is a useful tool for epidiemiological studies, it may not estimate insulin resistance as accurately as more invasive methods [16] .
Additionally the Busselton cohort is almost entirely Caucasian in ethnicity thus care must be taken before extrapolating our findings to other populations. All participants in the study were community-dwelling adults who volunteered to attend a study centre for assessment, making it less likely that they were unwell with intercurrent illness at the time of blood sampling.
Smaller studies have reported associations of higher ferritin with HOMA-R and with metabolic syndrome in both men and women [21, 25, 33] . One study of non-diabetic adults comprising 140 men and 277 women showed a correlation between ferritin level and HOMA-R in women but not in men [34] . Given the size of our study population and the coefficients demonstrated, any clinically or statistically significant influence of ferritin on HOMA-R in men is unlikely to be present. There was no statistically significant association of ferritin with HOMA-R in women in our cohort.
There are limited data documenting effects of venesection on diabetes risk. One study of 28 patients with Type 2 diabetes reported improved insulin sensitivity and lower HbA1c after venesection [7] . Another in 64 adults with metabolic syndrome showed no difference in HOMA-R in control and phlebotomy groups [35] . Therefore additional studies are needed to test whether manipulation of ferritin levels whether by phlebotomy, iron chelation therapy or dietary iron restriction would improve glucose metabolism. Putative mechanisms include reduction in cellular iron levels influencing enzymatic reactions in which iron is a cofactor, to changes in inflammation, cytokine profiles or other metabolic effects [1, 2] . However, it remains plausible that mild to moderate elevation of ferritin in the context of Type 2 diabetes reflects underlying inflammation. Our results suggest that in future studies, consideration should be given to assessing both iron-dependent and independent pathways by which reduction of ferritin levels could ameliorate the risk of diabetes.
Conclusions
In summary, serum ferritin levels are a robust biomarker for diabetes risk in men and women.
The association of higher serum ferritin levels with diabetes is not attributable to presence of cardiometabolic risk factors or inflammatory markers such as CRP. However, the absence of parallel associations of serum iron or transferrin saturation with diabetes in the same cohort suggests that ferritin captures influences beyond iron availability which contribute to diabetes risk.
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